Sarah B Gitto, PhD
Department: Pathology and Laboratory Medicine
Contact information
Stellar Chance Laboratories
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
Publications
Education:
B.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Permanent linkB.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Selected Publications
Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Fawell MD: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 15(1): 63, Jun 2025 Notes: doi: 10.1186/s13550-025-01256-0.Babazada H, Martorano P, Lee H, Geng S, Batra V, Maris JM, Pryma DA, Gitto SB, Farwell MD.: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 15(1): 63, June 2025.
Gitto SB, Pantel AR, Maxwell K, Pryma DA, Farwell MD, O'Brien SR, Clark AS, McDonald ES: [18F]FlourThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications Medicine 5(1): 90, March 2025 Notes: doi: 10.1038/s43856-025-00791-0.
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL.: [18F]Fluorthanatrace PET in ovarian cancer: Comparison with [18F]FDG PET, lesion location, tumor grade, and breast cancer gene mutation status. Journal of Nuclear Medicine 66(1): 34-39, January 2025 Notes: doi: 10.2967/jnumed.124.267627.
Gitto SB, Medvedev S, Anderson M, Simpkins F, Powell DJ: Anti-angiogenics enhance immune checkpoint inhibitor efficacy in ovarian cancer. Journal for ImmunoTherapy of Cancer 12(supplement 2), November 2024 Notes: doi: 10.1136/jitc-2024-SITC2024.0769.
Gitto SB, Ihewulezi CN, Onecha V, Lee H, Suarez-Garcia D, Bosque J, Simpkins F, Bertolet A, Pryma DA: PARP-targeted theranostic radiopharmaceutical therapy for drug-resistant ovarian cancer. European Journal of Cancer 211(supplement 4)): 114580, October 2024 Notes: Doi: https://doi.org/10.1016/j.ejca.2024.114580.
Riad A, Gitto SB, Mach RH: Lipid metabolism and synthesis pathway analysis of Sigma-2 Receptor and Progesterone Membrane Component 1 to develop novel cancer cell therapies. European Journal of Cancer 211: 114580, October 2024 Notes: DOI: 10.1016/j.ejca.2024.114613.
Babazada H, Martorano P, Lee H, Gitto SB, Ihewulezi CN, Samanta M, Batra V, Maris JM, Farwell MD, Pryma DA: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 51: S465-S465, September 2024.
Onecha VV, Bosque J, Suarez-Garcia D, Gitto SB, Ihewulezi C, Lee H, Pryma DA, Bertolet A: Time-driven dosimetry tool for in-vitro RPT experiments. AAPM 66th Annual Meeting and Exhibition July 2024.
Onecha VV, Suarez-Garcia D, Gitto SB, Lee H, Ihewulezi CN, Pryma D, Bertolet A: Space-and time-heterogeneous dosimetry for in vivo targeted alpha therapy. Journal of Nuclear Medicine 65(supplement 2): 242047, June 2024.